Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Dec;10(6):e003105.
doi: 10.1136/bmjdrc-2022-003105.

The Effect of high temperature on the stability of basal insulin in a pen: a randomized controlled, crossover, equivalence trial

Affiliations
Randomized Controlled Trial

The Effect of high temperature on the stability of basal insulin in a pen: a randomized controlled, crossover, equivalence trial

Tanawan Kongmalai et al. BMJ Open Diabetes Res Care. 2022 Dec.

Abstract

Introduction: Insulin is an essential medicine in the management of diabetes. When stored at high temperatures(HTs), its efficacy could rapidly decline. Therefore, appropriate storage of in-use insulin is necessary to achieve its maximum therapeutic effects. However, the ambient temperature in tropical countries is normally relatively high. This study aimed to compare the efficacies of basal insulin in a pen previously kept at 37°C for 21 days and basal insulin in a refrigerated pen (2°C-8°C). Continuous glucose monitoring (CGM) was used to evaluate daily mean glucose levels (MGLs).

Research design and methods: This randomized controlled, crossover, equivalence trial recruited adults with type 2 diabetes mellitus and glycated hemoglobin levels <8% who had used insulin glargine for >3 months. Subjects were randomized for sequential use of refrigerated basal insulin followed by basal insulin kept at HT, with a 2-week washout between phases. The HT insulin pens were stored in a 37°C incubator for 21 days before use, while the refrigerated insulin pens were stored at 2°C-8°C. Study patients received 7-day CGM. The primary outcome was the difference in the groups' MGLs. The secondary outcome parameters were glucose variability represented by the standard deviation (SD), mean amplitude of glycemic excursion (MAGE), and percentage of time in range (TIR). The remaining quantity of insulin was evaluated by ultrahigh-performance liquid chromatography (UHPLC) assay.

Results: Forty patients completed the study. The MGLwas 158.7±30.5 mg/dL and 157.0±40.9 mg/dL in the HT and refrigerated insulin pen groups, respectively (p=0.72). The groups had no significant differences in MAGE7day, SD, percentage of TIR, carryover period, or treatment effects (all p>0.05). There was also no significant difference in the remaining quantity of insulin evaluated by UHPLC (p=0.97).

Conclusions: HT basal insulin pens retain their potency and have biological activity comparable to that of refrigerated pens.Trial registration number TCTR20210611002.

Keywords: Continuous Glucose Monitoring; Diabetes Mellitus, Type 2; Insulin; Patient Education as Topic.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Flow diagram of study participants. HT, high temperature.
Figure 2
Figure 2
Glucose variability profile from continuous glucose monitoring compared between the previously kept in HT and refrigerated insulin pen groups: (A) coefficient of variation, (B) SD, (C) MAGE, and (D) percentage of TIR. HT, high temperature; MAGE, mean amplitude of glycemic excursion; TIR, time in range.

References

    1. International Diabetes Federation . IDF diabetes atlas. 10th edn. Brussels, Belgium: International Diabetes Federation, 2021.
    1. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–72. 10.1056/NEJMoa0802987 - DOI - PubMed
    1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group. Lancet 1998;352:837–53. 10.1016/S0140-6736(98)07019-6 - DOI - PubMed
    1. Grajower MM, Fraser CG, Holcombe JH, Daugherty ML, et al. . How long should insulin be used once a vial is started? Diabetes Care 2003;26:2665–9. 10.2337/diacare.26.9.2665 - DOI - PubMed
    1. Weiss M. Design of ultra-stable insulin analogues for the developing world. Journal of Health Specialties 2013;1:59–70. 10.4103/1658-600X.114683 - DOI

Publication types

Associated data